Month: March 2026

LIFT Closes Acquisition with SOQUEM for an Additional 25% Interest in the Galinée Property, Quebec

Written by Customer Service on March 9, 2026. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, March 09, 2026 (GLOBE NEWSWIRE) — Li-FT Power Ltd. (“LIFT” or the “Company”) (TSXV: LIFT) (OTCQX: LIFFF) (Frankfurt: WS0) is pleased to announce further to its December 15, 2025 and February 24, 2026 press releases that it has closed its acquisition of an additional 25% interest in the exclusive exploration rights commonly known as the Galinée property (“Galinée Property”) from SOQUEM Inc. (“SOQUEM”). Following closing, LIFT now holds a 75% interest in the Galinée Property, with the remaining 25% interest continuing to be held by SOQUEM. LIFT is the operator of the Galinée Property under joint venture with SOQUEM. Under the terms of the purchase agreement with SOQUEM (the “SOQUEM Agreement”), consideration for SOQUEM’s 25% interest in the Galinée Property consisted of 1,000,000 common shares in the...

EMGS: Non-binding term sheet for asset transaction

Written by Customer Service on March 9, 2026. Posted in Public Companies.

Reference is made to the previous stock exchange announcements and information published by Electromagnetic Geoservices ASA (the “Company” or “EMGS”) regarding the Company’s financial situation, including the Company’s interim financial report for the fourth quarter of 2025 published on 11 February 2026 and the stock exchange announcements published on 2 January 2026 and 1 October 2025. As previously announced, the Company has been evaluating all available strategic alternatives in order to safeguard the interests of its stakeholders. EMGS has signed a non-binding term sheet with an undisclosed independent, third-party (the “Buyer”) for a transaction (the “Transaction”) under which the Buyer will acquire EMGS’ business operations and assets, including hardware, IPR, contractual...

Pulsar Helium Provides Update on Transaction With Oscillate PLC

Written by Customer Service on March 9, 2026. Posted in Mergers And Acquisitions.

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS CASCAIS, Portugal, March 09, 2026 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“Pulsar” or the “Company”), a primary helium company, provides an update following its announcements on November 4, 2025, December 19, 2025, January 21, 2026, and February 10, 2026, regarding its option to acquire up to 100% of the shares of Quantum Hydrogen...

Ascom reports solid 2025 full-year results

Written by Customer Service on March 9, 2026. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LRBaar, Switzerland, 9 March 2026 Ascom’s 2025 financial year marked an important step forward. The Company strengthened its operational performance and while challenges remain, the progress underlines that Ascom is moving in the rightdirection. SUMMARY OF THE FINANCIAL RESULTS 2025Net revenue: CHF 292.1 million (2024: CHF 286.7 million), growth of 3.8% at constant currencies and 1.9% at actual currencies EBITDA: CHF 34.3 million (2024: CHF 21.3 million), EBITDA margin of 11.7% (2024: 7.4%) Group profit: CHF 15.1 million (2024: CHF 3.7 million), earnings per share CHF 0.43 (2024: CHF 0.10) Net cash position: CHF 29.6 million as of 31 December 2025 (2024: CHF 18.6 million) Equity ratio: 40.0% (2024: 39.2%)Shareholder distributionDividend proposal: CHF 0.20 per share Share buyback program: As...

WeRide and Geely Farizon to Deliver 2,000 Purpose-Built Robotaxi GXRs by 2026, Advancing Large-Scale Global Commercialization

Written by Customer Service on March 9, 2026. Posted in Public Companies.

GUANGZHOU, China, March 08, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, today signed an expanded strategic cooperation agreement with Geely’s Zhejiang Farizon New Energy Commercial Vehicle Group (Geely Farizon). The two companies announced plans to deliver 2,000 upgraded, purpose-built, mass-produced Robotaxi GXRs by 2026, advancing WeRide’s progress toward large-scale global Robotaxi commercialization. As part of the signing ceremony, the companies also showcased the upgraded Robotaxi GXR. The new model is scheduled to officially roll off the production line in the third quarter of 2026. As of January 2026, WeRide’s global Robotaxi fleet had 1,023 vehicles. With the addition of 2,000 new Robotaxi GXRs, WeRide expects its global operating Robotaxi fleet...

Hinen Introduces 3kW Cost-Effective Off-Grid and 12kW High-Power Hybrid Solutions at Solar & Storage Live Africa 2026

Written by Customer Service on March 9, 2026. Posted in Public Companies.

JOHANNESBURG, March 09, 2026 (GLOBE NEWSWIRE) — Hinen will present its latest residential and commercial energy storage solutions at Solar & Storage Live Africa 2026, taking place from 25–27 March 2026 at the Johannesburg Expo Centre. Exhibiting at Booth H5-G46 together with its South African distributor, SOLAR ENERGY DISTRIBUTOR, Hinen will highlight high-performance, cost-effective systems tailored to South Africa’s ongoing energy challenges—particularly load-shedding, rising electricity costs, and increasing demand for energy independence. Cost-Effective Off-Grid Solution Debuting in South Africa N3300S 3kW Off-Grid Inverter + B2560 2.56kWh Low-Voltage Battery Making its first appearance in South Africa, the N3300S + B2560 combination delivers an affordable and practical entry-level backup solution for residential users...

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

Written by Customer Service on March 8, 2026. Posted in Public Companies.

– New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history – – Data expand on previously reported results demonstrating that z-rostudirsen treatment led to sustained functional improvement across multiple clinical measures – WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced additional positive data from the ongoing Phase 1/2 DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. These data are being presented in a late-breaking poster...

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

Written by Customer Service on March 8, 2026. Posted in Public Companies.

– HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 – – 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment – – Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory endpoints will assess muscle function, CNS manifestations, and patient- and clinician-reported outcomes – – HARMONIA trial design and protocol aligned with FDA; trial intended to serve as confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications – WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular...

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Written by Customer Service on March 8, 2026. Posted in Public Companies.

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET. Investor Conference Call & Webcast InformationTo access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN. The live webcast may be accessed via the Investors section...

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

Written by Customer Service on March 8, 2026. Posted in Public Companies.

VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026.Conference Call/Webcast Information: Date: Monday, March 9, 2026 Time: 8:00 am ET (5:00 am PT) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID: 7885306 A live webcast of the company presentation will be available on the Investors section...

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals